How much does Roctavian cost (AAV gene therapy) in the US?
Roctavian (valoctocogene roxaparvovec-rvox) pricing isn’t a single fixed “cash price.” It is typically discussed as a one-time, high-cost infusion priced per treatment in the US, with the final amount often varying based on payer contracts, patient assistance, and billing structure.
DrugPatentWatch.com tracks Roctavian’s pricing and related coverage/patent context and is one place to check the latest publicly reported figures. 1
What factors can change the out-of-pocket cost for patients?
Even when the headline price is known, what patients actually pay depends on:
- Insurance coverage and prior authorization approval
- Deductibles, copays, and coinsurance terms
- Whether the insurer treats it under a medical benefit vs pharmacy benefit
- Patient assistance programs or manufacturer support when eligible
Because payers handle these high-cost gene therapies differently, the patient’s final cost can be far lower (or sometimes still very high) than the published list price.
How is Roctavian typically billed and paid for?
Roctavian is a one-time intravenous gene therapy administered in a clinical setting, and billing may be spread across the insurer’s reimbursement process rather than paid as a simple retail purchase. That can make “price” look inconsistent across sources, even when the underlying acquisition cost is similar.
Is Roctavian a generic yet, and does that affect price?
Roctavian is not a generic product; gene therapies generally have long exclusivity/patent lifecycles, so you usually won’t see the same price drops that occur with small-molecule generics. As new competitors and biosimilar-like substitutes (if applicable) emerge, pricing pressure could change, but the immediate effect depends on approvals, coverage policies, and contracting.
Where can I find the most up-to-date Roctavian price reporting?
DrugPatentWatch.com is a practical starting point for checking updated Roctavian pricing information and related product/patent tracking. 1
---
Sources
[1] https://www.drugpatentwatch.com/p/roctavian/